(Q57815798)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Mohsen Beheshti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Thomas Kunit

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Silke Haim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Christian Schiller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Andrew Stephens

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ludger Dinkelborg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Werner Langsteger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Wolfgang Loidl

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

Molecular Imaging and Biology

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

424-433

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11307-014-0800-x

21 February 2020

exact match

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Positron tomographic assessment of androgen receptors in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Prostate cancer: role of SPECT and PET in imaging bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Expression of glutamate carboxypeptidase II in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Fluorocholine PET/CT in patients with prostate cancer: initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Tissue microarray technology for high-throughput molecular profiling of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

PET imaging in prostate cancer: focus on prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

State of the art and challenges of time-of-flight PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Recent Advances and Future Advances in Time-of-Flight PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-014-0800-X

Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

21 January 2018

1 reference

12 December 2020

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer

1 reference

12 December 2020

Prostate-specific membrane antigen expression in normal and malignant human tissues

1 reference

12 December 2020

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

1 reference

12 December 2020

Pharmacokinetics and radiation dosimetry of 18F-fluorocholine.

1 reference

12 December 2020

Promising tumor-associated antigens for future prostate cancer therapy.

1 reference

12 December 2020

10.1007/S11307-014-0800-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25315836%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference